Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Beleave

CNSX:BE
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BE
CNSX
CA$15M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Beleave Inc. operates as a medical cannabis company in Canada. The last earnings update was 85 days ago. More info.


Add to Portfolio Compare Print
  • Beleave has significant price volatility in the past 3 months.
BE Share Price and Events
7 Day Returns
0%
CNSX:BE
-0.3%
CA Pharmaceuticals
0.6%
CA Market
1 Year Returns
-72.7%
CNSX:BE
-58.6%
CA Pharmaceuticals
5.3%
CA Market
BE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Beleave (BE) 0% 0% -14.3% -72.7% -90.5% -
CA Pharmaceuticals -0.3% -11.8% -9.2% -58.6% 15.6% 325.1%
CA Market 0.6% 1% 4.5% 5.3% 7.4% 14.9%
1 Year Return vs Industry and Market
  • BE underperformed the Pharmaceuticals industry which returned -58.6% over the past year.
  • BE underperformed the Market in Canada which returned 5.3% over the past year.
Price Volatility
BE
Industry
5yr Volatility vs Market

Value

 Is Beleave undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Beleave to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Beleave.

CNSX:BE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:BE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.4%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.685 (1 + (1- 26.5%) (82.92%))
1.069
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.07
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.44% + (1.069 * 5.44%)
7.25%

Discounted Cash Flow Calculation for CNSX:BE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Beleave is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:BE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 7.25%)
2020 7.73 Est @ 28.8% 7.21
2021 9.32 Est @ 20.59% 8.11
2022 10.71 Est @ 14.85% 8.68
2023 11.87 Est @ 10.83% 8.97
2024 12.82 Est @ 8.01% 9.03
2025 13.59 Est @ 6.04% 8.93
2026 14.23 Est @ 4.66% 8.71
2027 14.75 Est @ 3.69% 8.42
2028 15.20 Est @ 3.02% 8.09
2029 15.58 Est @ 2.54% 7.74
Present value of next 10 years cash flows CA$83.00
CNSX:BE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$15.58 × (1 + 1.44%) ÷ (7.25% – 1.44%)
CA$271.88
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$271.88 ÷ (1 + 7.25%)10
CA$134.97
CNSX:BE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$83.00 + CA$134.97
CA$217.97
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$217.97 / 509.86
CA$0.43
CNSX:BE Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$0.43
Current discount Discount to share price of CA$0.03
= -1 x (CA$0.03 - CA$0.43) / CA$0.43
93%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Beleave is available for.
Intrinsic value
>50%
Share price is CA$0.03 vs Future cash flow value of CA$0.42751
Current Discount Checks
For Beleave to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Beleave's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Beleave's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Beleave's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Beleave's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.05
CNSX:BE Share Price ** CNSX (2020-02-21) in CAD CA$0.03
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 16.05x
Canada Market PE Ratio Median Figure of 509 Publicly-Listed Companies 16.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Beleave.

CNSX:BE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BE Share Price ÷ EPS (both in CAD)

= 0.03 ÷ -0.05

-0.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beleave is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Beleave is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Beleave's expected growth come at a high price?
Raw Data
CNSX:BE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.55x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.15x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Beleave, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Beleave's assets?
Raw Data
CNSX:BE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$0.01
CNSX:BE Share Price * CNSX (2020-02-21) in CAD CA$0.03
Canada Pharmaceuticals Industry PB Ratio Median Figure of 154 Publicly-Listed Pharmaceuticals Companies 1.5x
Canada Market PB Ratio Median Figure of 2,339 Publicly-Listed Companies 1.41x
CNSX:BE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BE Share Price ÷ Book Value per Share (both in CAD)

= 0.03 ÷ 0.01

2.06x

* Primary Listing of Beleave.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beleave is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Beleave's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Beleave has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Beleave expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Beleave has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Beleave expected to grow at an attractive rate?
  • Unable to compare Beleave's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Beleave's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Beleave's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:BE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 69%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 40.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Canada Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BE Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:BE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 3 6 -23
2019-06-30 3 1 -25
2019-03-31 2 -9 -34
2018-12-31 1 -13 -30
2018-09-30 1 -19 -24
2018-06-30 0 -16 -20
2018-03-31 -6 -13
2017-12-31 -3 -12
2017-09-30 -3 -11
2017-06-30 -2 -11
2017-03-31 -1 -9
2016-12-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Beleave is high growth as no earnings estimate data is available.
  • Unable to determine if Beleave is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Beleave Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BE Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:BE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.05
2019-06-30 -0.06
2019-03-31 -0.08
2018-12-31 -0.08
2018-09-30 -0.08
2018-06-30 -0.07
2018-03-31 -0.05
2017-12-31 -0.06
2017-09-30 -0.06
2017-06-30 -0.06
2017-03-31 -0.06
2016-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Beleave will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Beleave's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Beleave's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Beleave's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Beleave has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Beleave performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Beleave's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Beleave does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Beleave's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Beleave's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Beleave's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Beleave Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 3.32 -22.80 7.38 0.01
2019-06-30 2.88 -25.01 11.73 0.01
2019-03-31 2.37 -33.78 21.32 0.01
2018-12-31 1.33 -30.32 24.72 0.08
2018-09-30 0.52 -23.57 23.19 0.08
2018-06-30 0.21 -19.53 17.97 0.15
2018-03-31 -12.64 10.44 0.15
2017-12-31 -11.95 11.60 0.08
2017-09-30 -11.00 10.74 0.08
2017-06-30 -11.22 11.10 0.02
2017-03-31 -8.55 8.49 0.02
2016-12-31 -3.19 3.10 0.03
2016-09-30 -4.15 2.63 0.05
2016-06-30 -3.07 1.51 0.04
2016-03-31 -2.99 1.42 0.06
2015-12-31 -3.10 1.41 0.12
2015-09-30 -1.23 1.03 0.10
2015-06-30 -0.93 0.95 0.03
2015-03-31 -0.51 0.38 0.08
2014-03-31 -0.84 0.75 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Beleave has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Beleave has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Beleave improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Beleave's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Beleave has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Beleave's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Beleave's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Beleave's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Beleave's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Beleave's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Beleave Company Filings, last reported 4 months ago.

CNSX:BE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 7.24 11.01 0.13
2019-06-30 9.39 10.80 0.37
2019-03-31 10.39 10.85 0.54
2018-12-31 20.59 10.65 1.76
2018-09-30 18.30 6.07 3.58
2018-06-30 16.44 7.23 9.55
2018-03-31 9.39 6.80 12.00
2017-12-31 10.91 5.01 13.35
2017-09-30 1.97 0.00 0.78
2017-06-30 2.72 0.00 1.39
2017-03-31 3.02 0.00 2.06
2016-12-31 2.80 0.00 1.84
2016-09-30 0.90 0.00 1.38
2016-06-30 0.57 0.00 0.16
2016-03-31 0.47 0.00 0.23
2015-12-31 1.19 -0.10 0.12
2015-09-30 1.28 0.00 0.19
2015-06-30 0.89 0.00 0.23
2015-03-31 0.87 0.00 0.23
2014-03-31 1.03 0.00 1.11
  • Beleave's level of debt (151.9%) compared to net worth is high (greater than 40%).
  • Unable to establish if Beleave's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Beleave has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Beleave has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 50.9% per year.
X
Financial health checks
We assess Beleave's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Beleave has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Beleave's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Beleave dividends.
If you bought CA$2,000 of Beleave shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Beleave's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Beleave's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 336 Stocks 3.4%
Canada Minimum Threshold Dividend Yield 10th Percentile 1%
Canada Bottom 25% Dividend Yield 25th Percentile 1.9%
Canada Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:BE Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Beleave has not reported any payouts.
  • Unable to verify if Beleave's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Beleave's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Beleave has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Beleave's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Beleave afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Beleave has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Beleave's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kevin Keagan
COMPENSATION CA$668,650
TENURE AS CEO 0.2 years
CEO Bio

Mr. Kevin Keagan has been Chief Executive Officer of Beleave Inc. since December 19, 2019 and serves as its Director since February 19, 2019. He serves as Chief Communications Officer of Beleave Inc. since October 2018. Mr. Keagan served as Interim Chief Financial Officer of Beleave Inc. since February 19, 2019 until December 19, 2019. He was a Treasurer of Beleave Inc. Mr. Keagan has extensive experience, with several years in capital markets, working within the financial services industry to provide oversight to the operation, expansion, and direction of Beleave’s communications and capital markets initiatives. Having spent few years as Head of Equity Trading at two of the largest asset Managers in Canada, Mr. Keagan offers a unique insight to the inner workings of not only the investment decision-making process, but he also developed a close working relationship with broker dealers and investment Managers on a global scale. Mr. Keagan was a Board Member of both the Canadian Securities Trader Association and Institutional Equity Trader Association. He holds the CIM designation.

CEO Compensation
  • Insufficient data for Kevin to compare compensation growth.
  • Kevin's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Beleave management team in years:

1
Average Tenure
  • The average tenure for the Beleave management team is less than 2 years, this suggests a new team.
Management Team

Kevin Keagan

TITLE
CEO, Chief Communications Officer & Director
COMPENSATION
CA$669K
TENURE
0.2 yrs

Roger Ferreira

TITLE
Co-Founder & Chief Science Officer
COMPENSATION
CA$466K
AGE
33

Bill Panagiotakopoulos

TITLE
COO & Director
COMPENSATION
CA$2M
AGE
43
TENURE
0.3 yrs

Justin Kosalka

TITLE
Director of Operations

Myles Fontaine

TITLE
VP of Sales
TENURE
1.6 yrs

Dana Gidlow

TITLE
Head of Veteran Affairs & Community Outreach
TENURE
3.7 yrs
Board of Directors Tenure

Average tenure of the Beleave board of directors in years:

1
Average Tenure
  • The average tenure for the Beleave board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kevin Keagan

TITLE
CEO, Chief Communications Officer & Director
COMPENSATION
CA$669K
TENURE
1 yrs

Bill Panagiotakopoulos

TITLE
COO & Director
COMPENSATION
CA$2M
AGE
43
TENURE
4.2 yrs

Andrew Steane

TITLE
Independent Director & Member of Advisory Board
TENURE
1 yrs

Jeannette VanderMarel

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
12. Jul 19 Sell Roger Ferreira Individual 09. Jul 19 12. Jul 19 -280,000 CA$0.07 CA$-20,931
15. Apr 19 Sell Roger Ferreira Individual 15. Apr 19 15. Apr 19 -150,000 CA$0.10 CA$-15,000
08. Mar 19 Sell Roger Ferreira Individual 04. Mar 19 04. Mar 19 -100,000 CA$0.11 CA$-10,500
X
Management checks
We assess Beleave's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Beleave has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Beleave Inc.'s (CNSX:BE) Path To Profitability

They expect the company to post a final loss in 2020, before turning a profit of CA$7.7m in 2021. … Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is extremely buoyant. … Next Steps: This article is not intended to be a comprehensive analysis on BE, so if you are interested in understanding the company at a deeper level, take a look at BE’s company page on Simply Wall St.

Simply Wall St -

Should You Be Worried About Insider Transactions At Beleave Inc. (CNSX:BE)?

So we'll take a look at whether insiders have been buying or selling shares in Beleave Inc. … Check out our latest analysis for Beleave Beleave Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the , Gordon Harvey, sold CA$75k worth of shares at a price of CA$0.21 per share. … Over the last year we saw more insider selling of Beleave shares, than buying.

Simply Wall St -

Can We See Significant Insider Ownership On The Beleave Inc. (CNSX:BE) Share Register?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Taking a look at our data on the ownership groups (below), it's seems that. … institutions don't own many shares in the company

Simply Wall St -

Have Insiders Been Selling Beleave Inc. (CNSX:BE) Shares?

That means that an insider was happy to buy shares at above the current price … It's very possible they regret the purchase, but it's more likely they are bullish about the company … It's not at all bad to see insiders buy shares at or above current prices.

Simply Wall St -

What Kind Of Shareholders Own Beleave Inc. (CNSX:BE)?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … With a market capitalization of CA$55m, Beleave is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Beleave Inc's (CNSX:BE) Balance Sheet Strong Enough To Weather A Storm?

Beleave Inc (CNSX:BE) is a small-cap stock with a market capitalization of CA$86.3m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Loss-Making Beleave Inc (CNSX:BE) Expected To Breakeven

Beleave Inc., together with its subsidiary, First Access Medical Inc., operates as a medical cannabis company in Canada. … The company’s loss has recently broadened since it announced a -CA$8.55m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$11.95m, moving it further away from breakeven? … The most pressing concern for investors is BE’s path to profitability – when will it breakeven

Simply Wall St -

Company Info

Description

Beleave Inc. operates as a medical cannabis company in Canada. The company cultivates and sells medical and recreational cannabis products. It also operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. The company sells its products through operating stores and online. Beleave Inc. is headquartered in Oakville, Canada.

Details
Name: Beleave Inc.
BE
Exchange: CNSX
Founded:
CA$15,295,806
509,860,225
Website: http://beleave.com
Address: Beleave Inc.
2030 Bristol Circle,
Suite 115,
Oakville,
Ontario, L6H 0H2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BE New Common Shares Canadian National Stock Exchange CA CAD 31. Dec 2015
OTCPK BLEV.F New Common Shares Pink Sheets LLC US USD 31. Dec 2015
DB 4B9 New Common Shares Deutsche Boerse AG DE EUR 31. Dec 2015
Number of employees
Current staff
Staff numbers
0
Beleave employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/22 02:53
End of day share price update: 2020/02/21 00:00
Last estimates confirmation: 2018/07/31
Last earnings filing: 2019/11/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.